









Markets
/
Stocks
/
nasdaq-prfx
/

PainReform Ltd

PRFX



View Detailed Chart

1.480USD

+0.060+4.23%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.18MMarket Cap

LossP/E TTM



PainReform Ltd

1.480

+0.060+4.23%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

+4.23%

5 Days

+4.23%

1 Month

-37.55%

6 Months

-46.57%

Year to Date

-55.89%

1 Year

-50.83%

View Detailed Chart

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

134 / 175

Overall Ranking

606 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 65.92.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 221.75K shares, decreasing 16.07% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.21.